CD274 and neoplasm: Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of many tumors, inducing durable responses in some cases, Tumor mutational load, CD8+ T cell density and Programmed cell Death Ligand−1 (PD-L1) expression have each been proposed as distinct biomarkers of response to PD-1/-L1 antagonists.